American Journal of Ophthalmology
Volume 146, Issue 5 , Pages 688-691.e2 , November 2008

Effect of Bevacizumab on Human Corneal Endothelial Cells: A Six-month Follow-up Study

  • Chun-Chi Chiang

      Affiliations

    • Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan
    • Institute of Medical and Molecular Toxicology, Chung Shan Medical University, Taichung, Taiwan
    • ,
  • Wen-Lu Chen

      Affiliations

    • Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan
    • ,
  • Jane-Ming Lin

      Affiliations

    • Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan
    • ,
  • Yi-Yu Tsai

      Affiliations

    • Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan
    • Corresponding Author InformationInquiries to Yi-Yu Tsai, Department of Ophthalmology, China Medical University Hospital, No. 2, Yue-Der Road, Taichung, Taiwan

,Accepted 4 June 2008.

References 

  1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  2. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111–118
  3. Yoganathan P, Deramo VA, Lai JC, et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina. 2006;26:994–998
  4. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495–511
  5. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90:1316–1321
  6. Luke M, Warga M, Ziemssen F, et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol. 2006;90:1178–1182
  7. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262–269
  8. Manzano RP, Peyman GA, Khan P, et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257–261
  9. Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol. 2007;91:1230–1233
  10. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:270–274
  11. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855–859
  12. Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977–982
  13. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand. 2004;82:557–563
  14. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514–2522
  15. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007;125:1363–1366
  16. Kernt M, Welge-Lüßen U, Yu A, Neubauer AS, Kampik A. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe. 2007;104:965–971
  17. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina. 2006;26:512–518
  18. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascularization age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331–335
  19. Bashshur ZF, Bazarbachi A, Schakal A, Haddad Z, El Haibi C, Noureddin B. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1–9
  20. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383–390

PII: S0002-9394(08)00434-0

doi: 10.1016/j.ajo.2008.06.002

American Journal of Ophthalmology
Volume 146, Issue 5 , Pages 688-691.e2 , November 2008

Article Tools